Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Vantictumab
OMP-18R5 · 3 trials · 3 indications
The maximum tolerated dose (MTD) will be determined in patients treated with vantictumab in combination with weekly nab-paclitaxel
| Arm | Type | Description |
|---|---|---|
| Docetaxel | EXPERIMENTAL | Drug: Docetaxel - administered intravenously |
| vantictumab | EXPERIMENTAL | Drug: vantictumab - administered intravenously |
| Vanctictumab (OMP-18R5) | EXPERIMENTAL | Vantictumab will be administered by intravenous (IV) infusion. |
| Nab-Paclitaxel | EXPERIMENTAL | Nab-Paclitaxel will be administered by intravenous (IV) infusion. |
| Gemcitabine | EXPERIMENTAL | Gemcitabine will be administered by intravenous (IV) infusion. |
| Name | Type | Description |
|---|---|---|
| Docetaxel | DRUG | Docetaxel will be administered IV. |
| vantictumab | DRUG | Vantictumab will be administered intravenously |
| Nab-Paclitaxel | DRUG | Nab-Paclitaxel will be administered by intravenous (IV) infusion. |
| Gemcitabine | DRUG | Gemcitabine will be administered by intravenous (IV) infusion. |
| OMP-18R5 | BIOLOGICAL | IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression. |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥18 years * Histologically documented recurrent or advanced (Stage IV) NSCLC * Eastern CooperativeOncology Group (ECOG) performance status of 0 or 1 * All acute treatmentrelated toxicity from prior therapy must have resolved to Grade ≤ 1 prio...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
OMP-18R5 is an investigational monoclonal antibody being studied for the treatment of solid tumors. It was evaluated in a Phase 1 dose escalation study in adults with solid tumors. It is not approved for any indication and remains in clinical development.
OMP-18R5 is being developed by Mereo BioPharma Group plc, which trades under the ticker MREO. The company is the sponsor of the clinical program for this monoclonal antibody in oncology.
OMP-18R5 is in Phase 1 clinical development. It has completed one Phase 1 trial in patients with solid tumors. The drug is investigational and has not been approved by the FDA for any use.
OMP-18R5 has been studied in one clinical trial, NCT01345201, titled A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors. The Phase 1 trial enrolled 35 participants in the United States and is now completed.
No, OMP-18R5 is not FDA approved. It is an investigational monoclonal antibody that has completed a single Phase 1 dose escalation trial in solid tumors. Further clinical development would be required before any regulatory approval could be considered.